Cargando…

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists

In recent years, peroxisome proliferator-activated receptor gamma (PPARγ) has been reported to be a target for the treatment of type II diabetes. Furthermore, it has received attention for its therapeutic potential in many other human diseases, including atherosclerosis, obesity, and cancers. Recent...

Descripción completa

Detalles Bibliográficos
Autor principal:	Tsukahara, Tamotsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368591/ https://www.ncbi.nlm.nih.gov/pubmed/22693486 http://dx.doi.org/10.1155/2012/362361

Ejemplares similares

Lysophospholipid-Related Diseases and PPARγ Signaling Pathway
por: Tsukahara, Tamotsu, et al.
Publicado: (2017)

PPARγ Networks in Cell Signaling: Update and Impact of Cyclic Phosphatidic Acid
por: Tsukahara, Tamotsu
Publicado: (2013)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonist and Angiotensin II Receptor Antagonist Ameliorate Renal Tubulointerstitial Fibrosis
por: Han, Jee-Young, et al.
Publicado: (2010)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

PPARγ in Complex with an Antagonist and Inverse Agonist: a Tumble and Trap Mechanism of the Activation Helix
por: Frkic, Rebecca L., et al.
Publicado: (2018)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

PTB-Associated Splicing Factor (PSF) Is a PPARγ-Binding Protein and Growth Regulator of Colon Cancer Cells
por: Tsukahara, Tamotsu, et al.
Publicado: (2013)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

Anticancer Role of PPARγ Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes
por: Simpson-Haidaris, P. J., et al.
Publicado: (2010)

Identification of an irreversible PPARγ antagonist with potent anticancer activity
por: Peng, Youyi, et al.
Publicado: (2020)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
por: Kulkarni, Ajit A., et al.
Publicado: (2012)

The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria
por: Serghides, Lena
Publicado: (2012)

Regulation of Glial Cell Functions by PPAR-γ Natural and Synthetic Agonists
por: Bernardo, Antonietta, et al.
Publicado: (2008)

PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments
por: Veliceasa, Dorina, et al.
Publicado: (2008)

Identification of Bexarotene as a PPARγ Antagonist with HDX
por: Marciano, David P., et al.
Publicado: (2015)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands: From Agonist to Antagonist
por: Miyachi, Hiroyuki
Publicado: (2023)

The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review
por: Liu, Yu, et al.
Publicado: (2020)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

PPAR-γ Agonist GW1929 But Not Antagonist GW9662 Reduces TBBPA-Induced Neurotoxicity in Primary Neocortical Cells
por: Wojtowicz, Anna K., et al.
Publicado: (2013)

PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer
por: Ballav, Sangeeta, et al.
Publicado: (2022)

Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα + γ Agonists
por: Oleksiewicz, Martin B., et al.
Publicado: (2008)

PPAR-γ Agonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer
por: Belfiore, A., et al.
Publicado: (2009)

FRI026 PPARγ Antagonists Induce Aromatase Transcription In Human Adipose Tissue Cells
por: Ardenkjær-Skinnerup, Jacob, et al.
Publicado: (2023)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity
por: Basu-Roy, Upal, et al.
Publicado: (2016)

PPAR Agonists and Metabolic Syndrome: An Established Role?
por: Botta, Margherita, et al.
Publicado: (2018)

The Role of PPARγ in Hepatocellular Carcinoma
por: Borbath, Ivan, et al.
Publicado: (2008)

Bronchopulmonary Dysplasia: Crosstalk Between PPARγ, WNT/β-Catenin and TGF-β Pathways; The Potential Therapeutic Role of PPARγ Agonists
por: Lecarpentier, Yves, et al.
Publicado: (2019)

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
por: Heudobler, Daniel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ec786tapkigegrg4sricu5cefb